arrow_back Back to App

Increased Funding and Focus on Sickle Cell Disease Treatment and Research until 2028.

This bill reauthorizes the sickle cell disease prevention and treatment demonstration program with increased funding. It expands the scope to include the treatment and prevention of complications associated with the disease. Additionally, it allows for grants, contracts, or cooperative agreements to be awarded to entities carrying out these tasks.
Key points
Annual funding is increased from $4.455 million to $8.205 million for fiscal years 2024 through 2028.
The scope of programs is expanded to include the prevention and treatment of complications of sickle cell disease.
Funding mechanisms are updated to include grants, contracts, or cooperative agreements.
It is the sense of Congress that further research should be undertaken to find cures for heritable blood disorders.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1852
Sponsor: Sen. Scott, Tim [R-SC]
Process start date: 2023-06-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1852.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-07.

What are the main provisions?

Key points include:

  • Annual funding is increased from $4.455 million to $8.205 million for fiscal years 2024 through 2028.
  • The scope of programs is expanded to include the prevention and treatment of complications of sickle cell disease.
  • Funding mechanisms are updated to include grants, contracts, or cooperative agreements.
  • It is the sense of Congress that further research should be undertaken to find cures for heritable blood disorders.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Scott, Tim [R-SC].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 201.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health